Zolgensma, Novartis one-time gene therapy for the treatment of spinal muscular atrophy, is waiting the FDA market authorization within the month. The swiss company’s CEO said that the price for the gene therapy will be far lower than the rumors of $4-5 millions. The current treatment for SMA is Spinraza, a Biogen product, with a list price of $750000 for the initial year, and $375000 annually thereafter